Роль рецепторов, активирующих пролиферацию пероксисом, в контроле алкогольной зависимости и лечении сопутствующих заболеваний печени

Семененя И. Н.; Шляхтун А. Г.; Радута Е. Ф.

Роль рецепторов, активирующих пролиферацию пероксисом, в контроле алкогольной зависимости и лечении сопутствующих заболеваний печени

Семененя И. Н., Шляхтун А. Г., Радута Е. Ф.

2019

https://doi.org/10.29235/1814-6023-2019-16-2-244-256

Настоящий обзор посвящен систематизации разрозненных данных о биологической роли рецепторов, активирующих пролиферацию пероксисом (PPARs), и изучению возможности использования агонистов PPARs в лечении пациентов с алкогольной зависимостью и сопутствующими заболеваниями печени. Рассмотрены наиболее важные работы последних лет, раскрывающие терапевтический потенциал агонистов PPARs в качестве средств для лечения пациентов с алкогольной зависимостью.

Семененя И. Н., Шляхтун А. Г., Радута Е. Ф. Роль рецепторов, активирующих пролиферацию пероксисом, в контроле алкогольной зависимости и лечении сопутствующих заболеваний печени. Известия Национальной академии наук Беларуси. Серия медицинских наук. 2019;16(2):244-256. https://doi.org/10.29235/1814-6023-2019-16-2-244-256

Цитирование

Список литературы

1. Miller, P. M. Medical treatment of alcohol dependence: a systematic review / P. M. Miller, S. W. Book, S. H. Stewart // Int. J. Psychiatry Med. – 2011. – Vol. 42, N 3. – P. 227–266. https://doi.org/10.2190/PM.42.3.b

2. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors / C. Dreyer [et al.] // Cell. – 1992. – Vol. 68, N 5. – P. 879–887. https://doi.org/10.1016/0092-8674(92)90031-7

3. Issemann, I. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators / I. Issemann, S. Green // Nature. – 1990. – Vol. 347, N 6294. – P. 645–650. https://doi.org/10.1038/347645a0

4. Diﬀerential expression and activation of a family of murine peroxisome proliferator-activated receptors / S. A. Kliewer [et al.] // Proc. Natl. Acad. Sci. – 1994. – Vol. 91, N 15. – P. 7355–7359. https://doi.org/10.1073/pnas.91.15.7355

5. Grygiel-Górniak, B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review / B. Grygiel-Górniak // Nutr. J. – 2014. – Vol. 13. – Art. 17. https://doi.org/10.1186/1475-2891-13-17

6. Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inﬂammation / J. Becker [et al.] // Pulm. Pharmacol. Ther. – 2008. – Vol. 21, N 2. – P. 324–330. https://doi.org/10.1016/j.pupt.2007.08.001

7. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms / E. Mueller [et al.] // J. Biol. Chem. – 2002. – Vol. 277, N 44. – P. 41925–41930. https://doi.org/10.1074/jbc.M206950200

8. Brunmeir, R. Functional regulation of PPARs through post-translational modifcations / R. Brunmeir, F. Xu // Int. J. Mol. Sci. – 2018. – Vol. 19, N 6. – Art. 1738. https://doi.org/10.3390/ijms19061738

9. Rochette-Egly, C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation / C. Rochette-Egly // Cell Signal. – 2003. – Vol. 15, N 4. – P. 355–366. https://doi.org/10.1016/S0898-6568(02)00115-8

10. Zoete, V. Peroxisome proliferator-activated receptor structures: ligand specifcity, molecular switch and interactions with regulators / V. Zoete, A. Grosdidier, O. Michielin // Biochim. Biophys. Acta – Mol. Cell Biol. Lipids. – 2007. – Vol. 1771, N 8. – P. 915–925. https://doi.org/10.1016/j.bbalip.2007.01.007

11. Sonoda, J. Nuclear receptors: decoding metabolic disease / J. Sonoda, L. Pei, R. M. Evans // FEBS Lett. – 2008. – Vol. 582, N 1. – P. 2–9. https://doi.org/10.1016/j.febslet.2007.11.016

12. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors / H. E. Xu [et al.] // Mol. Cell. – 1999. – Vol. 3, N 3. – P. 397–403. https://doi.org/10.1016/S1097-2765(00)80467-0

13. Fatty acids, eicosanoids, and hypolipidemic agents identifed as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay / G. Krey [et al.] // Mol. Endocrinol. – 1997. – Vol. 11, N 6. – P. 779–791. https://doi.org/10.1210/mend.11.6.0007

14. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1 alpha in human skeletal muscle, but not lipid regulatory genes / M. J. Watt [et al.] // J. Mol. Endocrinol. – 2004. – Vol. 33, N 2. – P. 533–544. https://doi.org/10.1677/jme.1.01499

15. Siersbaek, R. PPARgamma in adipocyte diﬀerentiation and metabolism – novel insights from genome-wide studies / R. Siersbaek, R. Nielsen, S. Mandrup // FEBS Lett. – 2010. – Vol. 584, N 15. – P. 3242–3249. https://doi.org/10.1016/j.febslet.2010.06.010

16. Diﬀerential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPARalpha, -beta, and -gamma in the adult rat / O. Braissant [et al.] // Endocrinology. – 1996. – Vol. 137, N 1. – P. 354–366. https://doi.org/10.1210/endo.137.1.8536636.

17. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis / P. Lefebvre [et al.] // J. Clin. Invest. – 2006. – Vol. 116, N 3. – P. 571–580. https://doi.org/10.1172/JCI27989

18. Mechanism of action of fbrates on lipid and lipoprotein metabolism / B. Staels [et al.] // Circulation. – 1998. – Vol. 98, N 19. – P. 2088–2093. https://doi.org/10.1161/01.cir.98.19.2088

19. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism / S. Kersten [et al.] // FASEB J. – 2001. – Vol. 15, N 11. – P. 1971–1978. https://doi.org/10.1096/fj.01-0147com

20. PPAR alpha regulation of the immune response and autoimmune encephalomyelitis / Y. Yang [et al.] // PPAR Res. – 2008. – Vol. 2008. – Art. ID 546753. https://doi.org/10.1155/2008/546753

21. Cannabinoids and PPARalpha signaling / Y. Sun [et al.] // Biochem. Soc. Trans. – 2006. – Vol. 34, N 6. – P. 1095–1097. https://doi.org/10.1042/BST0341095

22. Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors alpha to stimulate hepatic apolipoprotein A-I secretion / N. R. Pandey [et al.] // Biochemistry. – 2008. – Vol. 47, N 6. – P. 1579–1587. https://doi.org/10.1021/bi702148f

23. The organization, promoter analysis, and expression of the human PPARgamma gene / L. Fajas [et al.] // J. Biol. Chem. – 1997. – Vol. 272, N 30. – P. 18779–18789. https://doi.org/10.1074/jbc.272.30.18779

24. PPARγ overexpression regulates cholesterol metabolism in human L02 hepatocytes / T. Han [et al.] // J. Pharmacol. Sci. – 2019. – Vol. 139, N 1. – P. 1–8. https://doi.org/10.1016/j.jphs.2018.09.013

25. Wang, S. PPARγ signaling and emerging opportunities for improved therapeutics / S. Wang, E. J. Dougherty, R. L. Danner // Pharmacol. Res. – 2016. – Vol. 111. – P. 76–85. https://doi.org/10.1016/j.phrs.2016.02.028

26. PPARgamma in the control of brown adipocyte diﬀerentiation / J. Nedergaard [et al.] // Biochim. Biophys. Acta – Mol. Cell Biol. Lipids. – 2005. – Vol. 1740, N 2. – P. 293–304. https://doi.org/10.1016/j.bbadis.2005.02.003

27. Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs / J. R. Barson [et al.] // Alcohol. – 2009. – Vol. 43, N 6. – P. 433–441. https://doi.org/10.1016/j.alcohol.2009.07.003

28. Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking / S. Stopponi [et al.] // Biol. Psychiatry. – 2011. – Vol. 69, N 7. – P. 642–649. https://doi.org/10.1016/j.biopsych.2010.12.010

29. Activation of PPARγ by pioglitazone potentiates the eﬀects of naltrexone on alcohol drinking and relapse in msP rats / S. Stopponi [et al.] // Alcoholism: Clin. Exp. Res. – 2013. – Vol. 37, N 8. – P. 1351–1360. https://doi.org/10.1111/acer.12091

30. Diﬀerent immune cells mediate mechanical pain hypersensitivity in male and female mice / R. E. Sorge [et al.] // Nat. Neurosci. – 2015. – Vol. 18, N 8. – P. 1081–1083. https://doi.org/10.1038/nn.4053

31. Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans / Y. A. Blednov [et al.] // Alcoholism: Clin. Exp. Res. – 2015. – Vol. 39, N 1. – P. 136–145. https://doi.org/10.1111/acer.12610

32. PPAR agonists: I. Role of receptor subunits in alcohol consumption in male and female mice / Y. A. Blednov [et al.] // Alcoholism: Clin. Exp. Res. – 2016. – Vol. 40, N 3. – P. 553–562. https://doi.org/10.1111/acer.12976

33. PPAR agonists: II. Fenofbrate and tesaglitazar alter behaviors related to voluntary alcohol consumption / Y. A. Blednov [et al.] // Alcoholism: Clin. Exp. Res. – 2016. – Vol. 40, N 3. – P. 563–571. https://doi.org/10.1111/acer.12972

34. Fenofbrate – a lipid-lowering drug – reduces voluntary alcohol drinking in rats / E. Karahanian [et al.] // Alcohol. – 2014. – Vol. 48, N 7. – P. 665–670. https://doi.org/10.1016/j.alcohol.2014.08.004

35. Влияние активаторов и ингибиторов каталазы на показатели фармакокинетики этанола и активность ферментов метаболизма этанола и ацетальдегида печени и мозга крыс / Л. Р. Бардина [и др.] // Биомед. химия. – 2010. – Т. 56, № 4. – С. 499–505.

36. PPAR agonists regulate brain gene expression: Relationship to their eﬀects on ethanol consumption / L. B. Ferguson [et al.] // Neuropharmacology. – 2014. – Vol. 86. – P. 397–407. https://doi.org/10.1016/j.neuropharm.2014.06.024

37. Новые фармакологические подходы в терапии алкогольной зависимости: агонисты PPAR-рецепторов / А. Г. Шляхтун [и др.] // Современные проблемы биохимии и молекулярной биологии : сб. науч. ст., Гродно, 17–18 мая 2018 г. / НАН Беларуси, Ин-т биохимии биол. активных соединений НАН Беларуси ; под общ. ред. И. Н. Семенени, А. Г. Мойсеенка. – Минск, 2018. – С. 730–735.

38. Kelley, K. W. Alcoholism and inﬂammation: neuroimmunology of behavioral and mood disorders / K. W. Kelley, R. Dantzer // Brain Behav. Immun. – 2011. – Vol. 25, Suppl. 1. – P. S13–S20. https://doi.org/10.1016/j.bbi.2010.12.013

39. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inﬂammation / C. Blanquart [et al.] // J. Steroid. Biochem. Mol. Biol. – 2003. – Vol. 85, N 2–5. – P. 267–273. https://doi.org/10.1016/S0960-0760(03)00214-0

40. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels / S. Aleshin [et al.] // Mol. Pharmacol. – 2009. – Vol. 76, N 2. – P. 414–424. https://doi.org/10.1124/mol.109.056010

41. Nan, Y.-M. Peroxisome proliferator-activated receptor α, a potential therapeutic target for alcoholic liver disease / Y.-M. Nan, R.-Q. Wang, N. Fu // World J Gastroenterol. – 2014. – Vol. 20, N 25. – P. 8055–8060. https://doi.org/10.3748/wjg.v20.i25.8055

42. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice / L. Kong [et al.] // Lipids Health. Dis. – 2011. – Vol. 10. – Art. 246. https://doi.org/10.1186/1476-511X-10-246

43. Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking / C. Wu [et al.] // Hepatology. – 2011. – Vol. 54, N 6. – P. 1966–1974. https://doi.org/10.1002/hep.24645

44. Hepatic peroxisome proliferator-activated receptor gamma signaling contributes to alcohol-induced hepatic steatosis and inﬂammation in mice / W. Zhang [et al.] // Alcohol Clin. Exp. Res. – 2016. – Vol. 40, N 5. – P. 988–999. https://doi.org/10.1111/acer.13049

45. The ameliorating eﬀect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats / S. Liu [et al.] // Eur. J. Pharmacol. – 2011. – Vol. 650, N 1. – P. 384–389. https://doi.org/10.1016/j.ejphar.2010.09.082

46. Zhang, F. Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fbrogenesis / F. Zhang, Y. Lu, S. Zheng // Cell. Signal. – 2012. – Vol. 24, N 3. – P. 596–605. https://doi.org/10.1016/j.cellsig.2011.11.008

47. PPARδ agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair / M. Pang [et al.] // J. Hepatol. – 2009. – Vol. 50, N 6. – P. 1192–1201. https://doi.org/10.1016/j.jhep.2009.01.021

48. Diﬀerential activation of catalase expression and activity by PPAR agonists: implications for astrocyte protection in anti-glioma therapy / N. K. H. Khoo [et al.] // Redox Biol. – 2013. – Vol. 1, N 1. – P. 70–79. https://doi.org/10.1016/j.redox.2012.12.006

49. Fenofbrate decreases radiation sensitivity via peroxisome proliferator-activated receptor α-mediated superoxide dismutase induction in HeLa cells / X. Liu [et al.] // Radiat. Oncol. J. – 2012. – Vol. 30, N 2. – P. 88–95. https://doi.org/10.3857/roj.2012.30.2.88

Источник

Информация

Автор

Семененя И. Н. Институт биохимии биологически активных соединений НАН Беларуси
Шляхтун А. Г. Институт биохимии биологически активных соединений НАН Беларуси
Радута Е. Ф. Институт биохимии биологически активных соединений НАН Беларуси

Страницы

244-256

Год издания

2019

Ключевые слова

Коллекции

Известия Национальной академии наук Беларуси. Серия медицинских наук